PITTSBURGH, Oct. 24, 2018 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced its sponsorship of the Third International Symposium on Sigma-2 Receptors: Role in Health and Disease. The Symposium will be held in San Diego, California on November 3, 2018 beginning at 8:00 a.m. PT during Neuroscience 2018, the annual meeting of the Society for Neuroscience. The meeting is open to registered Neuroscience 2018 attendees.
The Third International Symposium on Sigma-2 Receptors is focused on advancing the understanding of the neurobiology of the sigma-2 receptors. The Symposium will feature a keynote address by Dr. Tara Spires-Jones, professor of neurodegeneration at the UK Dementia Research Institute and programme lead and deputy director of the Centre for Discovery Brain Sciences at the University of Edinburgh, Scotland, as well as a panel of expert speakers from the global sigma-2 community including:
- Wayne D. Bowen, Ph.D., Upjohn Professor of Pharmacology, professor of biology and chair of the department of molecular pharmacology, physiology and biotechnology, Brown University;
- Michael A. Cahill, Ph.D., lecturer in biochemistry and cell biology, Charles Sturt University in New South Wales, Australia;
- Timothy E. Kennedy, Ph.D., professor, department of neurology and neurosurgery, McGill University in Quebec, Canada;
- Robert H. Mach, Ph.D., Britton Chance Professor of Radiology, University of Pennsylvania;
- Stephen F. Martin, Ph.D., M. June and J. Virgil Waggoner Regents Chair in Chemistry, University of Texas at Austin;
- Aladdin A. Riad, Ph.D., postdoctoral fellow, University of Pennsylvania;
- Meharvan Singh, Ph.D., professor, department of pharmacology and neuroscience and interim executive director of the Institute for Healthy Aging, University of North Texas Health Science Center; and,
- Chenbo Zeng, Ph.D., research assistant professor of radiology, University of Pennsylvania.
In addition to scientific presentations by the speakers, Susan Catalano, Ph.D., founder and chief science officer of Cognition Therapeutics and Nicholas J. Izzo, Ph.D., principal scientist at Cognition Therapeutics, will report and discuss recent clinical trial outcomes of Elayta™, a sigma-2 receptor antagonist, in patients with Alzheimer’s disease.
Dr. Catalano commented, “Each year the International Symposium has grown along with the community of researchers interested in understanding of the role of sigma-2 receptors in neurological function and pathologies. This exceptional group of researchers is on the cutting edge of understanding and explaining the receptor’s role in diseases such as Alzheimer’s.”
The Third International Symposium on Sigma-2 Receptors: Role in Health and Disease will be held at Roy’s Restaurant at 333 West Harbor Drive in San Diego, CA. The event will be streamed live and will be archived on Cognition’s website at www.cogrx.com/our-events/. For more information, please contact Cari Moore at firstname.lastname@example.org.
About Cognition Therapeutics, Inc.
Cognition Therapeutics is a privately held biopharmaceutical company focused on the protection and restoration of synaptic function in neurocognitive disorders through a pipeline of disease-modifying small molecule drug candidates. Cognition’s lead candidate, Elayta™, is a proprietary first-in-class, orally available small molecule that has shown synaptorestorative potential and is in Phase 2 development for the treatment of mild-to-moderate Alzheimer’s disease. Dosing has commenced on two clinical studies of Elayta: SPARC (Synaptic Protection for Alzheimer’s Restoration of Cognition) and SNAP (AβO Displacement from Synapses on Neurons in Alzheimer’s Patients) and is anticipated to be initiated soon in the SHINE (Synaptic Health and Improvement of Neurological Function with Elayta) study. Elayta has been granted Fast Track designation by the U.S. FDA. Elayta and Cognition’s other pipeline candidates were identified using the company’s disease-relevant screening and novel chemistry platforms. Additional information about Cognition and its product candidates may be found online at https://cogrx.com.
This press release contains “forward-looking statements.” Forward-looking statements contained in this press release include, without limitation, statements regarding Cognition’s expectations regarding the clinical development of Elayta for the treatment of mild-to-moderate Alzheimer’s disease, the potential clinical benefits of Elayta for patients who have been diagnosed with Alzheimer’s disease, the expected enrollment and clinical trial timelines of Cognition’s SHINE, SPARC and SNAP trials, the expected results of Cognition’s SHINE, SPARC and SNAP trials and whether the results of Cognition’s preclinical studies and early clinical trials will be indicative of the results of the SHINE, SPARC and SNAP trials. In addition, words such as “may,” “believe,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, uncertainties and other factors that are outside of Cognition’s control. All forward-looking statements are based on Cognition’s expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Cognition undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.